Cambridge Cognition Holdings PLC’s Matthew Stork discusses progress on its new voice-based brain disease diagnostic and its pioneering work in the field of AI-based PTSD assessments.
A number of drugs are in development for PTSD, he says but only a couple are licensed currently, so this is potentially a major new area for the group.
It will add to new opportunities opening up in schizophrenia and neuro-oncology, he adds.
